Company Overview

Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases characterized by protein misfolding and synaptic dysfunction. The company operates within the biopharmaceutical and neuroscience therapeutics industries, with a primary emphasis on Alzheimer’s disease and related central nervous system disorders. Its core value proposition centers on targeting disease mechanisms upstream of amyloid plaque formation rather than plaque removal itself.

The company’s primary revenue drivers are research and development activities supported by equity financing, public offerings, and grant funding, as it does not currently generate commercial product revenue. Cognition Therapeutics is differentiated by its proprietary approach to modulating amyloid-beta oligomers, which are believed to play a key role in synaptic toxicity. The company was founded in 2007 and became publicly traded in 2021, evolving from an early-stage neuroscience research firm into a publicly listed clinical-stage drug developer.

Business Operations

Cognition Therapeutics’ operations are centered on the discovery, development, and clinical evaluation of therapeutic candidates targeting neurodegenerative diseases. Its primary business segment is drug discovery and clinical development, with a lead focus on oral, small-molecule compounds designed to penetrate the blood–brain barrier and stabilize synaptic function. The company’s lead asset, CT1812, is being evaluated in multiple clinical studies for Alzheimer’s disease and dementia with Lewy bodies.

Operational activities are primarily conducted in the United States, with clinical trials involving international research sites. Cognition Therapeutics relies on third-party contract research organizations for clinical trial execution and manufacturing, rather than owning large-scale production facilities. The company maintains intellectual property covering its sigma-2 receptor biology platform and associated compounds, which it considers a core technological asset.

Strategic Position & Investments

Strategically, Cognition Therapeutics is focused on advancing CT1812 through mid- to late-stage clinical development while expanding the potential application of its sigma-2 receptor platform to additional neurodegenerative indications. Growth initiatives are centered on achieving clinical milestones, securing regulatory alignment, and pursuing non-dilutive funding opportunities such as government and foundation grants.

The company has historically supplemented its capital base through public equity offerings and strategic collaborations rather than large-scale acquisitions. It does not maintain a broad portfolio of subsidiaries or diversified investments, instead concentrating resources on a limited number of clinical programs. Emerging areas of interest include broader applications of synaptic protection mechanisms in diseases beyond Alzheimer’s, though public disclosures indicate these efforts remain at an exploratory stage.

Geographic Footprint

Cognition Therapeutics is headquartered in Pennsylvania, United States, and its corporate and research activities are primarily U.S.-based. Clinical development programs extend across North America and select international regions, reflecting the global nature of late-stage neurological research and patient recruitment.

While the company does not maintain extensive international commercial operations, its clinical trial footprint and investor base provide it with an international presence. Any future expansion into global markets would be contingent on regulatory approvals and commercialization partnerships, particularly in Europe and Asia, where neurodegenerative disease prevalence represents significant unmet medical need.

Leadership & Governance

Cognition Therapeutics is led by an executive team with experience in neuroscience, pharmaceutical development, and public company management. The leadership emphasizes a science-driven strategy focused on translational research and disciplined capital allocation to advance clinical assets efficiently.

Key executives include:

• Lisa A. Ricciardi – President and Chief Executive Officer
• John P. Kelly – Chief Financial Officer
• James V. Sullivan – Chief Operating Officer
• Susan R. Abushakra – Chief Medical Officer
• Mary Ann E. Nahill – Chief Development Officer

The board and executive leadership articulate a governance philosophy centered on clinical rigor, regulatory compliance, and long-term shareholder value creation through innovation in neurodegenerative disease treatment.